Teva to Present Latest Data on AJOVY (fremanezumab-vfrm) Injection at the 2022 American Headache Society Annual Meeting

TEL AVIV, Israel & PARSIPPANY, N.J. – Teva Pharmaceuticals , a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced that eight abstracts examining real-world data to better understand the use of AJOVY (fremanezumab-vfrm) injection in patients with migraine will be presented at the 2022 American Headache Society (AHS) Annual Meeting held June 9-12, 2022 , in Denver, Colorado .

Read the source article at Stock Market Quotes and News
2022-06-10 13:14:43